Combinations of Drugs in the Treatment of Obesity

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2016 Oct 8

PMID 27713360

Citations 7

Authors

Bruno Halpern

Eduardo S L Oliveira

Andre M Faria

Alfredo Halpern

Maria Edna de Melo

Cintia Cercato

Marcio C Mancini

Affiliations

Soon will be listed here.

Abstract

Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.

Citing Articles

Challenges in the care and treatment of patients with extreme obesity.

Stumpf M, Mancini M Arch Endocrinol Metab. 2024; 68:e230335.

PMID: 39420906 PMC: 11326745. DOI: 10.20945/2359-4292-2023-0335.

Pharmacotherapy for obesity: moving towards efficacy improvement.

Coutinho W, Halpern B Diabetol Metab Syndr. 2024; 16(1):6.

PMID: 38172940 PMC: 10763391. DOI: 10.1186/s13098-023-01233-4.

Lupenone-Rich Fraction Derived from L. Suppresses Lipid Accumulation in 3T3-L1 Adipocytes.

Lakthan T, Limpachayaporn P, Rayanil K, Charoenpanich P, Phuangbubpha P, Charoenpanich A Life (Basel). 2023; 13(8).

PMID: 37629581 PMC: 10455188. DOI: 10.3390/life13081724.

Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Kwon Y, Lee H, Nam C, Chang H, Yoon Y, Lee H Diabetes Metab Syndr Obes. 2021; 14:941-950.

PMID: 33688228 PMC: 7936679. DOI: 10.2147/DMSO.S300342.

PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva.

Guan Z, Jacobs G, van Pelt H, van Gerven J, Burggraaf J, Zhao W Pharmacol Res Perspect. 2020; 8(2):e00574.

PMID: 32168433 PMC: 7069653. DOI: 10.1002/prp2.574.

References

Greenway F, Whitehouse M, Guttadauria M, Anderson J, Atkinson R, Fujioka K . Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2008; 17(1):30-9. DOI: 10.1038/oby.2008.461. View

Huang B, Liou H . Sibutramine-induced recurrent seizures. Epilepsy Behav. 2009; 15(3):399. DOI: 10.1016/j.yebeh.2009.05.001. View

Bray G . Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab. 2008; 93(11 Suppl 1):S81-8. PMC: 2585762. DOI: 10.1210/jc.2008-1294. View

Bray G . Is new hope on the horizon for obesity?. Lancet. 2008; 372(9653):1859-1860. DOI: 10.1016/S0140-6736(08)61792-4. View

Wadden T, Berkowitz R, Womble L, Sarwer D, Arnold M, STEINBERG C . Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res. 2000; 8(6):431-7. DOI: 10.1038/oby.2000.53. View

Ravussin E, Smith S, Mitchell J, Shringarpure R, Shan K, Maier H . Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009; 17(9):1736-43. PMC: 2754219. DOI: 10.1038/oby.2009.184. View

Lee M, Fujioka K . Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother. 2009; 10(11):1841-5. DOI: 10.1517/14656560903048959. View

Astrup A, Breum L, Toubro S, Hein P, QUAADE F . The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord. 1992; 16(4):269-77. View

Batterham R, Cohen M, Ellis S, le Roux C, Withers D, Frost G . Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003; 349(10):941-8. DOI: 10.1056/NEJMoa030204. View

10.

Weintraub M, Hasday J, Mushlin A, Lockwood D . A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984; 144(6):1143-8. View

11.

Padwal R, Kezouh A, Levine M, Etminan M . Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond). 2007; 31(10):1567-70. DOI: 10.1038/sj.ijo.0803631. View

12.

DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092-100. DOI: 10.2337/diacare.28.5.1092. View

13.

Greenway F, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K . Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009; 94(12):4898-906. DOI: 10.1210/jc.2009-1350. View

14.

Douketis J, Macie C, Thabane L, Williamson D . Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005; 29(10):1153-67. DOI: 10.1038/sj.ijo.0802982. View

15.

Astrup A, Toubro S, Christensen N, QUAADE F . Pharmacology of thermogenic drugs. Am J Clin Nutr. 1992; 55(1 Suppl):246S-248S. DOI: 10.1093/ajcn/55.1.246s. View

16.

Shekelle P, Hardy M, Morton S, Maglione M, Mojica W, Suttorp M . Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003; 289(12):1537-45. DOI: 10.1001/jama.289.12.1537. View

17.

Cummings D, Overduin J . Gastrointestinal regulation of food intake. J Clin Invest. 2007; 117(1):13-23. PMC: 1716217. DOI: 10.1172/JCI30227. View

18.

TRUANT A, Olon L, COBB S . Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res Clin Exp. 1972; 14(11):726-38. View

19.

Smith S, Aronne L, Burns C, Kesty N, Halseth A, Weyer C . Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008; 31(9):1816-23. PMC: 2518351. DOI: 10.2337/dc08-0029. View

20.

Padwal R . Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs. 2009; 10(10):1117-25. View